Tags

Type your tag names separated by a space and hit enter

Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease.
Clin Endocrinol (Oxf). 2004 May; 60(5):550-9.CE

Abstract

OBJECTIVE

To determine baseline characteristics and the effects of 2 years of GH replacement therapy on body composition, muscle strength, bone mass, and metabolic indices in GH-deficient (GHD) adults previously treated for pituitary-dependent Cushing's disease.

DESIGN

A single-centre, open-labelled, prospective study.

PATIENTS

Fifteen consecutive GHD adults previously treated for pituitary-dependent Cushing's disease (CD group) and 15 closely matched GHD adults with previous nonfunctioning hypopituitary disease (NF group) were included. All patients had adult-onset GH deficiency.

RESULTS

The mean dose of GH was similar in both study groups during the 2-year treatment. At baseline, diastolic blood pressure was higher, and lumbar (L2-L4) bone mineral density (BMD) was lower, in the CD group than in the NF group. The increase in lean mass in response to GH therapy, as measured by dual-energy X-ray absorptiometry (DEXA), was less marked in the CD group. GH replacement therapy reduced diastolic blood pressure only in the CD group. The patients in the CD group had greater treatment response in lumbar (L2-L4) spine BMD and in isometric and isokinetic knee extension strength than the patients in the NF group. At study end, no difference remained between the two study groups.

CONCLUSIONS

This study revealed differences in the baseline characteristics between GHD patients previously treated for Cushing's disease as compared with closely matched GHD patients with previous nonfunctioning hypopituitary disease. The 2-year GH replacement therapy eliminated all the differences between the two study groups.

Authors+Show Affiliations

Research Centre for Endocrinology and Metabolism, Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Göteborg, Sweden.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15104557

Citation

Johannsson, Gudmundur, et al. "Baseline Characteristics and the Effects of Two Years of Growth Hormone Replacement Therapy in Adults With Growth Hormone Deficiency Previously Treated for Cushing's Disease." Clinical Endocrinology, vol. 60, no. 5, 2004, pp. 550-9.
Johannsson G, Sunnerhagen KS, Svensson J. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clin Endocrinol (Oxf). 2004;60(5):550-9.
Johannsson, G., Sunnerhagen, K. S., & Svensson, J. (2004). Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clinical Endocrinology, 60(5), 550-9.
Johannsson G, Sunnerhagen KS, Svensson J. Baseline Characteristics and the Effects of Two Years of Growth Hormone Replacement Therapy in Adults With Growth Hormone Deficiency Previously Treated for Cushing's Disease. Clin Endocrinol (Oxf). 2004;60(5):550-9. PubMed PMID: 15104557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. AU - Johannsson,Gudmundur, AU - Sunnerhagen,Katharina Stibrant, AU - Svensson,Johan, PY - 2004/4/24/pubmed PY - 2004/7/28/medline PY - 2004/4/24/entrez SP - 550 EP - 9 JF - Clinical endocrinology JO - Clin Endocrinol (Oxf) VL - 60 IS - 5 N2 - OBJECTIVE: To determine baseline characteristics and the effects of 2 years of GH replacement therapy on body composition, muscle strength, bone mass, and metabolic indices in GH-deficient (GHD) adults previously treated for pituitary-dependent Cushing's disease. DESIGN: A single-centre, open-labelled, prospective study. PATIENTS: Fifteen consecutive GHD adults previously treated for pituitary-dependent Cushing's disease (CD group) and 15 closely matched GHD adults with previous nonfunctioning hypopituitary disease (NF group) were included. All patients had adult-onset GH deficiency. RESULTS: The mean dose of GH was similar in both study groups during the 2-year treatment. At baseline, diastolic blood pressure was higher, and lumbar (L2-L4) bone mineral density (BMD) was lower, in the CD group than in the NF group. The increase in lean mass in response to GH therapy, as measured by dual-energy X-ray absorptiometry (DEXA), was less marked in the CD group. GH replacement therapy reduced diastolic blood pressure only in the CD group. The patients in the CD group had greater treatment response in lumbar (L2-L4) spine BMD and in isometric and isokinetic knee extension strength than the patients in the NF group. At study end, no difference remained between the two study groups. CONCLUSIONS: This study revealed differences in the baseline characteristics between GHD patients previously treated for Cushing's disease as compared with closely matched GHD patients with previous nonfunctioning hypopituitary disease. The 2-year GH replacement therapy eliminated all the differences between the two study groups. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/15104557/Baseline_characteristics_and_the_effects_of_two_years_of_growth_hormone_replacement_therapy_in_adults_with_growth_hormone_deficiency_previously_treated_for_Cushing's_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0300-0664&date=2004&volume=60&issue=5&spage=550 DB - PRIME DP - Unbound Medicine ER -